Vesa Kataja
Impact in
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
Papers in
-
- Prostate Cancer Treatment and Research 20
- Prostate Cancer Diagnosis and Treatment 14
- Oncology 42
- Cancer Treatment and Pharmacology 10
- HER2/EGFR in Cancer Research 9
- Co-authors
- Heikki Joensuu (26 shared papers)Veli‐Matti Kosma (25 shared papers)Matti Uusitupa (19 shared papers)Chris Parker (3 shared papers)Alan Horwich (3 shared papers)Matti Eskelinen (21 shared papers)C. Bangma (1 shared paper)Petri Bono (19 shared papers)
- Journals
- Annals of Oncology (39 papers)Acta Oncologica (13 papers)Journal of Clinical Oncology (13 papers)Breast Cancer Research (4 papers)European Journal of Cancer (4 papers)
- Partner nations
- FinlandUnited KingdomFrance
In The Last Decade
Vesa Kataja
171 papers receiving 8.8k citations
Vesa Kataja's Hit Papers
Peers
Comparison fields: 5 of 147
- Cancer Research 1.7k
- Oncology 2.8k
- Pulmonary and Respiratory Medicine 1.7k
- Pathology and Forensic Medicine 660
- Genetics 925
Countries citing papers authored by Vesa Kataja
This map shows the geographic impact of Vesa Kataja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vesa Kataja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vesa Kataja more than expected).
Fields of papers citing papers by Vesa Kataja
This network shows the impact of papers produced by Vesa Kataja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vesa Kataja. The network helps show where Vesa Kataja may publish in the future.
Co-authors
The 25 scholars most cited alongside Vesa Kataja, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 176 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Hit paper breakdown → | 2014 | 967 |
| 2 | Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2010 | 493 |
| 3 | 2009 | 328 | |
| 4 | A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. | 2003 | 304 |
| 5 | 2004 | 292 | |
| 6 | 2012 | 233 | |
| 7 | Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. | 2001 | 206 |
| 8 | 2011 | 200 | |
| 9 | 2011 | 181 | |
| 10 | 2013 | 179 | |
| 11 | 2008 | 161 | |
| 12 | Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. | 2003 | 161 |
| 13 | 2014 | 154 | |
| 14 | Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. | 2001 | 153 |
| 15 | 2000 | 143 | |
| 16 | 2010 | 142 | |
| 17 | 2000 | 142 | |
| 18 | 2004 | 140 | |
| 19 | 2000 | 135 | |
| 20 | Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. | 1992 | 124 |
About Vesa Kataja
Vesa Kataja is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Molecular Biology, having authored 176 papers that have together received 9.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (20 papers), Breast Cancer Treatment Studies (17 papers), Prostate Cancer Diagnosis and Treatment (14 papers), Cervical Cancer and HPV Research (11 papers), Genital Health and Disease (10 papers), BRCA gene mutations in cancer (10 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (9 papers). The work is most often cited by research in Cancer Research (1.7k citations), Oncology (2.8k citations), Pulmonary and Respiratory Medicine (1.7k citations), Pathology and Forensic Medicine (660 citations) and Genetics (925 citations). Vesa Kataja has collaborated with scholars based in Finland, United Kingdom and France. Frequent co-authors include Heikki Joensuu, Veli‐Matti Kosma, Matti Uusitupa, Chris Parker, Alan Horwich, Matti Eskelinen, C. Bangma, Petri Bono, Taina Turpeenniemi‐Hujanen and Bernard Escudier. Their work appears in journals such as Annals of Oncology, Acta Oncologica, Journal of Clinical Oncology, Breast Cancer Research and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.